These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs. Gori M; Volterrani M; Piepoli M; Senni M Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659 [TBL] [Abstract][Full Text] [Related]
6. LCZ696 : a new paradigm for the treatment of heart failure? Minguet J; Sutton G; Ferrero C; Gomez T; Bramlage P Expert Opin Pharmacother; 2015 Feb; 16(3):435-46. PubMed ID: 25597387 [TBL] [Abstract][Full Text] [Related]
7. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837 [TBL] [Abstract][Full Text] [Related]
8. LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone. Kusaka H; Sueta D; Koibuchi N; Hasegawa Y; Nakagawa T; Lin B; Ogawa H; Kim-Mitsuyama S Am J Hypertens; 2015 Dec; 28(12):1409-17. PubMed ID: 25762811 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan. Chrysant SG J Am Soc Hypertens; 2017 Jul; 11(7):461-468. PubMed ID: 28652105 [TBL] [Abstract][Full Text] [Related]
10. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin-Neprilysin Inhibition as a Paradigm for All? Vaduganathan M; Desai AS Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488 [TBL] [Abstract][Full Text] [Related]
13. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure. Macdonald PS Clin Ther; 2015 Oct; 37(10):2199-205. PubMed ID: 26386501 [TBL] [Abstract][Full Text] [Related]
18. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure. Marques da Silva P; Aguiar C Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335 [TBL] [Abstract][Full Text] [Related]